Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Amazing that this is still trading. They keep their filings current, but no news in YEARS.
It's nice to see a little movement. What's going on with it? Still no news i've heard in years.
Overview
During the quarter ended, December 31, 2019, the Company continued to position its product, NovaDerm®, to enter clinical trials to gain FDA product approval. Having secured Orphan Drug Designation as a biologic for NovaDerm®, we complied with the FDA annual reporting requirements. In addition, as part of an asset purchase agreement, we granted Amarantus Bioscience Holdings, Inc., a right of first refusal for the purchase of any engineered skin technology designed for treatment of severe burns in humans that we developed. This right of first refusal expired during this quarter on November 7, 2019.
Recently, the risk of introducing pathogens when using materials from animals to produce drugs, devices, and biologics has increased awareness of the safety issues. NovaDerm® and future Regenicin products use animal sourced materials like collagen to produce the life-saving products. We have worked with our collagen supplier and the FDA to ensure we are meeting the expectations for traceability and purity of the FDA for NovaDerm® production. We have arranged for sufficient Bovine Closed Herd corium to produce sufficient collagen scaffolds to meet our needs for the clinical trials, ensuring compliance with FDA requirements.
Our major objective for 2021 is to secure the required funding to finalize some additional requirements of the IND application and begin the clinical trials. As previously reported, our goal in obtaining the required funding has been to minimize shareholders’ dilution as much as possible. Consequently, we are primarily pursuing financing through the issuance of debt instruments, international licensing agreements and governmental grants. We have completed all the administrative requirements to allow us to apply for grants. Regenicin is now registered with System For Award Management (“SAM”) which is required to do business with the US Government. We must have our IND submitted before we can request financial assistance from The US FDA Office of Orphan Products Clinical Trials Grant. We intend to take full advantage of working with OOPD to develop our clinical protocol according to suggestions from the FDA during our Pre-IND meeting.
The Orphan Drug Act created the Orphan Product Grants Program, which is administered by OOPD, to stimulate the development of promising products for rare diseases and conditions. Orphan product grants are a proven method of fostering and encouraging the development of new safe and effective medical products for rare diseases and conditions. These grants support new and continuing extramural research projects that test the safety and efficacy of promising new drugs, biologics, devices, and medical foods through human clinical trials in very vulnerable populations often with life-threatening conditions.
I was shocked to see that RGIN is still filing 10Qs and 10-Ks. They've been radio silent for three years now. Why keep filing if there is no hope in moving PermaDerm forward?
What happened here? It's only been 9 years of trying to raise $3M. By now he has asked everyone in the world. No takers. So apparently the world doesn't need this because for the last 9 years other products have been used. So is everyone sitting on their shares since so low? 154M outstanding and no one once to trade it around for fun!!!
I guess regenicin and pure med farma are dead men walking....
Classic today - the bid is .0001c, the offer is 200c...... I'm going out on a limb and say the .0001 is value.
Good summary Scottrader, the only person this thing has helped is McCoy. Pure scam.
Shareholders might as well sell out recouping what ever pennies are left of their dollar investment. Just look at the company progress, the PR's of achievement the quarterly and annual filings to see this one is a loser stock only lining the pockets of fatboy McCoy.
There are other companies actively using a derma product while McCoy continues to develop his product on paper that NO ONE seems to want.
It was a good story line, helping burn victim and Veterans, unfortunately that story line is useless, no one has been helped besides McCoy.
The only thing RGIN shareholders have banked on so far is the prospect of Hope,
Hope doesnt pay the bills
Could not agree with you more applevision. It amazes me. Even on this msg board, - on the company summary above, showing 5% shareholders, there are 2 Discala entities right there. If that doesn't scare everyone for miles, I don't know what would. I've concluded that this is the downside of the bell curve - always someone at one end or the other that will believe anything. I guess these are the same people who believe in chemtrails, and that the earth is flat. Lucky we are not all the same I guess.....
If you haven't figured out from submitted quarterly forms.
This is a pure scam. Deliberate false information and operating cash flow of a lemonade stand on the farthest cul-de-sac from civilization you can find.
This D-Bag has been milking this for over a decade
Agree that today was a nice surprise. Something around 5$ would be even better.
Well the positive takeaway from the share price increase is that it doesn't take much to move this stock in either direction. If and I repeat if mccoy is still alive and funding somehow comes to rgin this could make a really impressive move to the upside. I have little hope of this occurring but maybe hell will freeze over and ole fatboy actually comes thru for once.
Let's hope that sausage is not in the punchbowl.
1 4000 share buy way above the bid doesnt spell any accomplishments by McCoy. If the "funding" came through we'd see THOUSANDS of shares trading hands.
Longs know someone is smoking hopium
Up to a nickel on low volume. If it is sheik passadasausage at work here I hope he keeps passin da sausage.
the arab shiek passdasausage probably funded something Randy sold him on like Camel collagen gelato
OK...what happened? We jumped up nicely today. What's going on?
Call me a pessimist but on past form, the Suntrust transaction will turn out to be some kind of shady contra.
Nothing will happen in this ticker until $ flows---FINANCING.
They are looking for fianancing for three years.Wow!We are in dark.No communication.Hope for the best.
https://ih.advfn.com/stock-market/USOTC/regenicin-inc-pc-RGIN/stock-news/79271766/statement-of-ownership-sc-13g?_ga=2.49551974.1319945093.1550422987-87778604.1538099608
Why is this signed February 2019? I'm confused. The 10 million posted below by stkmaniac was given to another company called health care co.
Sun Trust bank has owned these 10M shares for a while, I think at least a year or so. we just never saw any announcement of how they were acquired. Obviously not bought in the open market because have not even traded that many shares, plus we would be higher in price with that many shares purchased. My guess they got some cash or they did some accounting work or something like that We don't know what price they were given at, if there are restrictions on selling or anything. I heard after the AMBS deal the cone of silence was lifted. Well no news EVER!!!!!!!
It has been 8 years now. So I would think thousands of burn victims are being treated with current technology and doing fine. If this was so great it would of been funded by now. We can only hope (which is never a good investment strategy) that things are at least progressing, but oh so slowly...
Definitely. I don't see suntrust jumping in here if this was going under. Big positive. Especially where this has been with the last year or 2 of radio silence.
New money is what we have been waiting to see. I read it as positive news.
Not sure unfortunately. I'm in the dark just like the rest of us. I also like what I'm hearing from configman because I actually heard a similar thing from a source that they are waiting on money that is being held up.
hans, any thoughts on how long such a development will take to impact operations and sp? TIA....agree this is positive.
Looks like suntrust is an institutional investor now with 10 million shares owning 6.5% of outstanding. Good sign. At least something is happening finally.
The Brooklyn Court comment might link to a comment I heard that they are suing Citigroup for 134 million. Something about money they are holding and won't release. Supposedly Morgan Stanley is a player in this drama also.
Brooklyn court records? What are you talking about. Have a link you can post?
Check Brooklyn court records on Jan 23rd....
Configman - I don't think he is doing anything against the new rules. The problem is that he and his team of Discala type brokers and advisors now face a tricky path in terms of how they sell stocks like RGIN. They have a legal duty to disclose things they didn't have to before. So the shares will tend to find their true market value as opposed to the pumped price.
Have not heard anything from NZ for a while. Just looked at their NZ website, they no longer falsely claim on that to own the Hikurangi facility, although McCoys own website does still make that false claim. The NZ website still implies they have assets etc there when they have nothing as far as my information says.
Agree...very good question...WTF?
As much as Mccoy is to blame for this awful stock price, who is the moron selling at one penny? What's the point?
Skept- Maybe you should tell us what Randy is doing that is counter to the new rules for penny stocks. You should touch base with your contact in New Zealand to see what is going on too.
Looks like the new SEC rules for penny stocks, that requires some actual ethical conduct - has been very damaging for McCoy.
Annual report out yesterday. No one even cares anymore haha...
Yup, your right. Very familiar ring to it.
Pure Farma is McCoys company also, correct?
Merry Christmas! Way to go fatboy mccoy!!
This is code for:
1, Randy needs a few greenbacks.
2, Lets try to boost some volume by speaking enigmatically of funding somehow from someone being just around the corner.
3, nothing happens except a little false hope
4, wait 4 months, rinse and repeat....
Followers
|
71
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
2931
|
Created
|
08/06/10
|
Type
|
Free
|
Moderators |
Regenicin, Inc.
10 High Court
Little Falls, NJ 07424
**updated and correct phone number** (973) 557-8914
they filed this on aug 22 2016- http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=11558959
Name: | Randall McCoy |
Title: | Principal Executive Officer and Director |
Date: | August 22, 2016 |
Name: | John J. Weber |
Title: | Principal Financial Officer and Director |
Date: | August 22, 2016 |
LITTLE FALLS, N.J., June 12, 2012 /PRNewswire/ -- Regenicin, Inc. (OTC Bulletin Board: RGIN) a biotechnology company specializing in the development of and commercialization of regenerative cell therapies to restore the health of damaged tissues and organs, announced today that the Food and Drug Administration (FDA) has granted Orphan Status approval for the PermaDerm® product, the only tissue-engineered skin prepared from autologous (patient's own) skin cells consisting of both epidermal and dermal layers, that is indicated for catastrophic burn patients. The FDA had previously designated PermaDerm® to be a biological/drug (permanent skin replacement) not a medical device (temporary skin replacement). PermaDerm® is the only skin replacement technology to receive this Biological/drug designation.
COMPANY HIGHLIGHTS:
PermaDerm™ is being developed to be the only tissue-engineered skin prepared from autologous (patient's own) skin cells consisting of both epidermal and dermal layers. A small harvested section of the patient's own skin can be grown to graft an area one hundred times its size in as little as thirty days.
These living, self-to-self skin graft tissue are intended to form permanent skin tissue that will not be rejected by the immune system of the patient, a critical possibility in porcine or cadaver skin grafts used today.
The technology has been clinically tested in over 150 pediatric, catastrophic burn patients. Currently Regenicin is working with its contract manufacturer to prepare for pre-market approval of PermaDerm™ from the FDA.
PermaDerm™ is being designed to save lives, reduce healthcare costs by decreasing the patient's stay in the Critical Care Unit and reduce the need for additional surgeries. An insurance company procedural code has been approved for reimbursement of costs to hospitals. The American Medical Association has assigned CPT (Current Procedural Terminology) code for cultured skin substitutes under the dermal substitute category which enables insurance companies to process and hospitals to be reimbursed for cultured skin substitutes once approved by the FDA.
According to the American Burn Association, there are currently over 2,000 cases annually involving burns covering over 50% of the patient's total body surface area.
PermaDerm™ is being developed for the treatment of catastrophic, full-thickness burns covering over 50% of the total body surface area.
PermaDerm™ has been used in clinical trials on pediatric patients with catastrophic burns covering from 50 to 90+% of their body.
PermaDerm™ is being developed to require less donor skin from the patient's own body, thus needing fewer surgeries to harvest skin. The result is expected to be less scarring, with fewer infections and faster healing.
Randall McCoy
Chief Executive Officer
Randall McCoy has more than 37 years of experience in the healthcare industry. His experience includes executive positions and scientific research and development. His previous employment includes George Washington University, Temple University Medical School and RCA/SRI International (Director of Life Sciences and Electronic Displays). Mr. McCoy has assisted both small and major pharmaceutical/device companies address FDA issues. He has also helped over 225 foreign and domestic companies introduce their FDA regulated drug and medical device products into the US and World market. Mr. McCoy currently has over 30 Patents US and International.
Changed to AMBS
Dr. Joseph Rubinfeld Ph.D
Director at CytRX; Initial Co-Founder of Amgen, Inc.
Dr. Joseph Rubinfeld co-founded SuperGen, Inc. in 1991 and has served as its Chief Executive Officer and President, Chief Scientific Officer and as a director. He has been a director of CytRX since July 2002. Dr. Rubinfeld is also a founder of JJ Pharma. Dr. Rubinfeld was one of the four initial founders of Amgen, Inc. in 1980 and served as a Vice President and its Chief of Operations until 1983. From 1987 until 1990, Dr. Rubinfeld was a Senior Director at Cetus Corporation and from 1968 to 1980, Dr. Rubinfeld was employed at Bristol-Myers Company. Dr. Rubinfeld received a B.S. degree in chemistry from C.C.N.Y. and an M.A. and Ph.D in chemistry from Columbia University.
John Weber
Regenicin™'s Interim CFO
John Weber most recently served as Executive Vice President of Fujifilm USA, the highest ranked American corporate officer, from 2006 until his departure in 2009. His responsibilities included overseeing all corporate activity with the exception of R&D. During that time Fujifilm was ranked as the fastest growing medical imaging company, consistently ranking #1 or #2 in customer satisfaction. From 1998 through 2006 he served as Senior Vice President, Operations at Fujifilm USA where he spearheaded the transition of the company from a film distributor to a digital medical informatics company. From 1986 until 1998 he served as CFO where he helped to profitably manage Fuji's growth from an employee base of 75 to over 1,000. Prior to his distinguished career at Fujifilm USA, Mr. Weber served as the CFO for the confectionary and drinks division of Cadbury Schweppes Limited for three years and as Corporate Controller for an additional five years.
Dr. Craig Eagle
Pfizer Oncology
Dr. Craig Eagle joined Pfizer Australia in 2001 as part of the medical group. In Australia, his role involved leading and participating in scientific research, regulatory and pricing & re-imbursement negotiations for compounds in therapeutic areas including oncology, anti-infectives, respiratory, arthritis and pain management. In 2003, Pfizer relocated Dr. Eagle to the United States where he was appointed as the worldwide lead for development of Celecoxib in oncology to oversee the global research program. Since that time he has had increasing responsibility for overseeing the global research plans and teams for Irinotecan and Dalteparin. In 2007, he became head of Medical Affairs and Outcomes Research for Pfizer, including the US oncology business. Dr. Eagle has led, or been directly involved with, teams that resulted in eight new products or indications. As part of his current role at Pfizer, he has led the integration of the Pfizer/Wyeth oncology businesses and portfolio.
The Broadsmoore Group, LLC 9,223,770(8)
560 Lexington Ave., 16 th Fl.
New York, NY 10022
PDA Associates LLC 7,770,000(9)
560 Lexington Ave., 16 th Fl.
New York, NY 10022
Officers, directors and 5 percent shareholders collectively 54,508,099(10) 59.74%
* Less than 1%
(1) Unless otherwise indicated, each person or entity named in the table has sole voting power and investment power (or shares that power with that person's spouse) with respect to all shares of common stock listed as owned by that person or entity.
(2) A total of 83,807,964 shares of the Company's common stock are considered to be outstanding pursuant to Rule 13d-3(d)(1) under the Securities Exchange Act of 1934.
(3) Includes 32,821,641 shares of common stock held in his name and options to purchase 885,672 shares of common stock.
(4) Includes 50,000 shares of common stock held in his name and options to purchase 885,672 shares of common stock,
(5) Includes 1,050,000 shares of common stock held in his name and options to purchase 885,672 shares of common stock
(6) Includes 50,000 shares of common stock held in his name and options to purchase 885,672 shares of common stock,
(7) Includes 33,971,641 shares of common stock, options to purchase 3,542,688 shares of common stock and shares of Series A Convertible Preferred Stock convertible into 3,350,000 shares of common stock,
(8) Includes 5,706,270 shares of common stock held in its name, warrants to purchase 167,500 shares of common stock and shares of Series A Convertible Preferred Stock convertible into 3,350,000 shares of common stock,
(9) Includes 7,400,000 shares of common stock held in its name and warrants to purchase 370,000 shares of common stock,
(10) Includes 47,077,911 shares of common stock, warrants to purchase 537,500 shares of common stock, options to purchase 3,542,688 shares of common stock and shares of Series A Convertible Preferred Stock convertible into 3,350,000 shares of common stock
http://ih.advfn.com/p.php?pid=nmona&article=5144097
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |